停用替诺福韦与恩替卡韦后不同的复发率及风险预测因素
前瞻性纳入100例停用3年恩替卡韦或富马酸替诺福韦二吡呋酯治疗的慢性乙型肝炎患者,发现停用替诺福韦者3个月病毒学复发率52.9%高于恩替卡韦者6.1%,临床复发率15.2%高于1.5%,但12个月复发率相当;治疗结束时HBsAg水平、CTLA4 rs231775非GG基因型及HLA-DPA1 rs3077 AA基因型可预测复发或持续临床应答。
要点
- 停用替诺福韦者3个月病毒学复发率52.9% vs 恩替卡韦者6.1%,临床复发率15.2% vs 1.5%,但12个月复发率相当。
- 治疗结束时HBsAg水平预测病毒学复发(HR 1.62)、临床复发(HR 1.78)和持续临床应答(OR 0.57)。
- CTLA4 rs231775非GG基因型预测病毒学复发(HR 1.74)和临床复发(HR 2.06),HLA-DPA1 rs3077 AA基因型预测持续临床应答(OR 10.84)。
核心结论
- 停用富马酸替诺福韦二吡呋酯治疗较停用恩替卡韦治疗与更早复发相关,需要针对不同核苷(酸)类似物进行治疗后监测。
研究设计与样本
- 前瞻性纳入100例正在停用核苷(酸)类似物治疗的慢性乙型肝炎患者,评估病毒和宿主复发预测因素及再治疗结局。
主要发现
- 停用替诺福韦者3个月病毒学复发率52.9% vs 停用恩替卡韦者6.1%(P < .001),临床复发率15.2% vs 1.5%(P = .007),12个月复发率相当。
- 治疗结束时HBsAg水平预测病毒学复发(HR 1.62;95%CI 1.19-2.21)、临床复发(HR 1.78;95%CI 1.13-2.81)和持续临床应答(OR 0.57;95%CI 0.35-0.94)。
- CTLA4(rs231775)非GG基因型预测病毒学复发(HR 1.74;95%CI 1.01-3.00)和临床复发(HR 2.06;95%CI 1.04-4.11)。
- HLA-DPA1(rs3077)AA基因型预测持续临床应答(OR 10.84;95%CI 1.12-105)。
- 停用核苷(酸)类似物治疗后1个月的HBV DNA是后续复发的早期预测因素。
临床怎么用
- 作者认为停用富马酸替诺福韦二吡呋酯治疗较停用恩替卡韦治疗与更早复发相关,需要针对不同核苷(酸)类似物进行治疗后监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated the patterns and predictors for virological relapse (VR), clinical relapse (CR), and sustained clinical response (SCR) and the outcomes of retreatment after nucleos(t)ide analogue (NUC) therapy discontinuation. METHODS: Patients with chronic hepatitis B who were discontinuing NUC therapy were prospectively enrolled. Viral and host predictors of relapse were evaluated, including hepatitis B virus (HBV) surface antigen (HBsAg) level, anti-HBV core antibody level, and presence of single-nucleotide polymorphisms in the genes encoding the receptors NTCP (rs2296651) and CTLA4 (rs231775) and in the 3' untranslated regions of the genes encoding HLA-DPA1 (rs3077) and HLA-DPB1 (rs9277535); posttherapy predictors of relapse were also investigated. Information about NUC retreatment and outcomes were recorded. RESULTS: Overall, 100 patients discontinuing 3-year entecavir (ETV) or tenofovir (TDF) therapy were enrolled. Patients discontinuing TDF exhibited significantly higher rates of VR (52.9% vs 6.1%; P < .001) and CR (15.2% vs. 1.5%, P = .007) at 3 months than those discontinuing ETV, but relapse rates at 12 months were comparable. The end-of-therapy HBsAg levels predicted VR (hazard ratio [HR], 1.62; 95% confidence interval [CI], 1.19-2.21), CR (HR, 1.78; 95% CI, 1.13-2.81), and SCR (OR, 0.57; 95% CI, .35-.94). The CTLA4 (rs231775) non-GG genotype predicted VR (HR, 1.74; 95% CI, 1.01-3.00) and CR (HR, 2.06; 95% CI, 1.04-4.11), while the HLA-DPA1 (rs3077) AA genotype predicted SCR (OR, 10.84; 95% CI, 1.12-105). The HBV DNA 1 month after NUC treatment cessation was an early predictor of subsequent relapse. CONCLUSIONS: Discontinuation of tenofovir disoproxil fumarate treatment rather than entecavir treatment is associated with earlier relapse, and NUC-specific posttherapy monitoring is necessary.
引用
- Su TH, Yang HC, Tseng TC, et al. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. J Infect Dis. 2018. PMID: 29300980. doi:10.1093/infdis/jix690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。